Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer

Thu-Huyen Pham1†, Yesol Bak1†, Taeho Kwon2, Sae-Bom Kwon1, Jae-Wook Oh3, Jong-Hyung Park4, Yang-Kyu Choi4, Jin Tae Hong5* and Do-Young Yoon1*

Abstract

Background: Tumor-associated macrophages can promote breast cancer metastasis by secreting cytokines and growth factors. Interleukin (IL)-32θ, a newly identified IL-32 isoform, was previously shown to down-regulate various proinflammatory factors of macrophages. Here, we report the presence of IL-32θ in breast cancer tissues and evaluate its effects on macrophage-regulated breast cancer metastasis.

Methods: RT-qPCR was used to analyze the mRNA expression of IL-32θ, Chemokine (C-C motif) ligand 18 (CCL18) in breast cancer tissues. In vitro cell-based experiments using IL-32θ-expressing MDA-MB-231 cells were conducted to examine the effects of IL-32θ on metastasis and its molecular signaling. In vivo xenograft, immunohistochemistry, and optical imaging models were generated to support in vitro and clinical findings.

Results: The clinical data displayed opposite expression patterns of CCL18 and IL-32θ mRNA in macrophage-infiltred breast tumor tissues compared with those in the other tissues tested. In MDA-MB-231 cells, IL-32θ overexpression attenuated migration, invasion, tumor-promoting factors, and increased epithelial markers levels upon treatment with conditioned media from THP-1-derived macrophages. Additionally, IL-32θ expression in a xenograft model led to a remarkable decrease in tumor size and macrophage-stimulated tumor promotion. This inhibition was mediated through a direct interaction with protein kinase C-δ (PKCδ), subsequently eliminating the downstream factors STAT3 and NF-κB. Blocking CCL18 during co-culture of macrophages and breast cancer cells reduced the levels of breast cancer progression-related factors and PKCδ downstream signaling suggesting CCL18 as the main macrophage-secreted factors triggering the signaling pathway inhibited by IL-32θ.

Conclusions: Our findings demonstrate a novel role of IL-32θ as an intracellular modulator to suppress macrophage-promoted breast cancer progression by targeting CCL18-dependent signaling.

Keywords: IL-32θ, Macrophage, Breast cancer metastasis, CCL18, PKCδ, STAT3

Background

Breast cancer is the most common cancer in females worldwide, and is also the leading cause of cancer-related death in the majority of countries [1]. Tumor progression is the process by which tumor cells acquire more aggressive and malignant characteristics, allowing them to invade microenvironments and subsequently migrate to distant organs [2, 3]. In this process, epithelial-mesenchymal transition (EMT) is one of the key events that allows tumor cells to switch to mesenchymal phenotypes to facilitate their migration, invasion, and metastasis [4]. This tumor metastasis and acquired resistance to tumor therapy is a result of the interaction between cancer cells and the tumor microenvironment, leading to the secretion of various factors that target cancer cells and manipulate their promotion [5–7].
Therefore, inhibition of these interactions can serve as a therapeutic approach in cancer.

Macrophages are the most abundant immune cells in the tumor microenvironment, which can occupy up to 50% of the entire tumor mass [8], and have been associated with poor outcomes in various carcinomas [9]. Macrophages can be classified into M1 and M2 macrophages, which polarize into the respective forms in response to an environmental change. M2 macrophages facilitate angiogenesis, tissue remodeling [10], and promote breast cancer progression by secreting angiogenic factors and breast tumor mitogens [11]. Tumor-associated macrophages (TAMs) are a type of M2 macrophages, and breast cancer TAMs display an alternative phenotype that promotes tumor invasion and metastasis [12]. Further, cancer cells can educate macrophages to enhance tumor development and metastasis [6]. Numerous studies have determined the relationship between breast cancer and macrophages, and cancer therapies targeting both breast cancer cells and macrophages are of great interest given their potential in the clinical setting.

Interleukin (IL)-32 was first reported as natural killer transcript 4 located on human chromosome 16p13.3 [13]. IL-32 has various isoforms due to alternative splicing [14], although the role of each isoform in disease remains controversial [15]. Among the IL-32 isoforms, our group discovered both IL-32β and IL-32 small fragment [14] and reported the functions of IL-32β in inflammation and cancer [16–18]. In the present study, we aimed to investigate the role of IL-32β in the breast cancer microenvironment and to determine whether IL-32β could suppress macrophage-induced breast cancer progression, and to explore the underlying molecular mechanisms.

Materials and methods
mRNA extraction from breast cancer tissue
The biospecimens including breast tissues (n = 90) and sera (n = 55), and the characteristic information of breast cancer patients used in this study were provided by the Biobank of Chonnam National University Hwasun Hospital (Hwasun-gun, Korea) and Korea University Guro Hospital (Seoul, Korea). RNA was extracted from frozen tissues using a homogenizer and TRI Reagent® (Ambion, Austin, TX), then reverse transcription was performed. qPCR was conducted using the M-MuLV reverse transcriptase (New England Biolabs, Beverly, MA) according to manufacturer’s instructions.

Cell culture and treatment
The MDA-MB-231 cell line (ATCC® HTB-26™, Manassas, VA) was cultured in DMEM (HyClone Laboratories, Logan, UT). The human monocytic cell line THP-1 (Korean Cell Line Bank, Seoul, Korea, KCLB-40202) was cultured in RPMI-1640 (HyClone). Both mediums were supplemented with 10% heat-inactivated fetal bovine serum (MilliporeSigma, Burlington, MA), 100 units/mL penicillin, and 100 μg/mL streptomycin at 37 °C/5% CO2. To generate the conditioned media (CM), THP-1 cells were stimulated with 100 nM phorbol ester (PMA) (MilliporeSigma) for 48 h, the non-attached cells were washed with phosphate buffered saline (PBS) followed by addition of fresh culture media, and these cells were then incubated for another 24 h. The CM was collected and centrifuged to remove the remaining cells.

Generation of the IL-32β-overexpressing cell line
We transfected MDA-MB-231 cells with the pcDNA3.1 (+)-6 × Myc-IL-32β vector or pcDNA3.1 (+)-6 × Myc-empty vector, as described previously [19] and refer as MDA-MB-231-IL-32β and MDA-MB-231-EV cells, respectively. In brief, the cells were seeded into 6-well plates (1 × 10^5 cells/well) and transfected with 3 μg of vector using Lipofectamine® 2000 (Invitrogen, Carlsbad, CA). Afterwards, the cells were selected using medium containing 700 μg/ml G-418 (Duchefa Biochemie BV, Haarlem, The Netherlands) for two weeks. G-418-resistant colonies were then pooled and expanded.

Migration and invasion assays
For the migration assay, cells (5 × 10^5 cells/mL) were seeded onto the upper chambers of 24-well transwell plates (Corning Inc., Corning, NY) in serum-free DMEM. For the invasion assay, each transwell chamber was coated with 30 μl of Matrigel (Corning) before breast cancer cells were added to the top chamber. The lower chamber contained 500 μl macrophage-derived CM. Cells migrated or invaded for 24 h at 37 °C/5% CO2, and non-migrated or non-invaded cells were removed from the chamber interior by a cotton swab. Attached cells to the lower surface of the chamber were stained using Diff-Quick Kit (Sysmex, Kobe, Japan). Migrated or invaded cells were quantitated by dissolving stained cells in 100 μl of 10% acetic acid and then the mixture was transferred to a 96-well plate for colorimetric reading at 620 nm.

Quantitative reverse transcription PCR (RT-qPCR)
The miRNA expression levels in breast cancer cells were detected by RT-PCR for IL-32β and RT-qPCR for other target genes. Total RNA was isolated using Easy-BLUE (iNtRON Biotechnology, SungNam, Korea), then cDNA was synthesized using the M-MuLV reverse transcriptase (New England Biolabs, Beverly, MA) according to manufacturer’s instructions. The mRNA expression levels in breast cancer cells were quantitated using the -ΔCt method (ΔCt = fluorescence threshold value; −ΔCt = Ct GAPDH − Ct target gene).
Enzyme-linked immunosorbent assay (ELISA)
Cells were cultured in the absence or presence of CM for 24 h, and then the culture media were replaced by fresh media for another 24 h. The cell culture supernatants were collected and analyzed using ELISA kits (R&D Systems, Minneapolis, MN) for human IL-1β, CCL5, CCL18, GM-CSF according to manufacturer’s instructions.

Immunoblotting and immunoprecipitation
For nuclear and cytoplasmic fractionation, cells were collected and fractionated using the NE-PER kit (Thermo Fisher Scientific, Waltham, MA) according to manufacturer’s instructions. For immunoprecipitation, cell lysates were mixed with specific antibodies and then pulled down by protein G-agarose beads. Samples were subjected to 10% SDS–PAGE before being transferred to PVDF membranes (MilliporeSigma). The membranes were blocked with 5% skim milk dissolved in Tris-buffered saline containing 0.05% Tween-20 followed by primary antibody incubation at 4°C overnight. After washing, horseradish peroxidase-conjugated IgG antibodies were added, and the membranes allowed to incubate for 1 h. Western blot was visualized using a chemiluminescence detection kit (Advastar, Cleveland, Ohio) and detected by EZ-capture MG protein imaging system (ATTO, Tokyo, Japan). Specific antibodies used include those against Myc-tag, Flag-tag and phosphotyrosine-STAT3 (MilliporeSigma); IkBa, p-IkBa, p65, p50, PARP, and E-cadherin (Cell Signaling Technology, Danvers, MA); STAT3, COX-2, GAPDH (Santa Cruz Biotechnology, Dallas, TX); and anti-CCL18 neutralizing antibody (Abcam, Cambridge, MA). The monoclonal antibody KU-32-52 to detect IL-32 was prepared as previously described [20]. The raw data of western blot results can be seen in Additional file 2.

Gelatin zymography
Cells (3 × 10⁵ cells/well) were seeded in a 6-well plate, cultured overnight, and then treated with or without CM for 24 h. MMP-9 activity in the supernatant was assayed as previously described [21]. Gel staining was conducted with InstantBlue™ (MilliporeSigma) for 30 min in the dark. Areas of gelatinolytic degradation appeared as transparent bands on the blue background.

Immunofluorescence
Cells were seeded on coverslips and incubated overnight. The attached cells were fixed, and permeabilized with cold acetone before blocking with 0.1% bovine serum albumin in PBS at room temperature (RT). Primary antibodies were added (1:100) to the coverslip incubating at 4°C overnight. After washing with PBS, the coverslips were incubated with secondary antibodies at (1:200). Nuclei staining was performed by exposing to 4, 6-diamidino-2-phenylindole (1:2000) (MilliporeSigma) for 20 s. The stained cells were visualized using an upright fluorescence microscope (Olympus, Tokyo, Japan).

Xenograft model and optical imaging
All animal procedures were conducted according to the guidelines of the Institutional Animal Care and Use Committee (IACUC No. KU17008) of Konkuk University. MDA-MB-231-EV and MDA-MB-231-IL-32θ cells (5 × 10⁶ cells) were subcutaneously injected with Matrigel into the flanks of 5-week-old female athymic BALB/c nude mice (Nara Bio, Seoul, Korea). After 35 days, the tumors were harvested from euthanized mice. The tumor tissues were fixed with 10% formalin buffer, embedded in paraffin, and sectioned in 3 μm thickness for use in immunohistochemical analyses. Tumor volume was calculated using the formula V(mm³) = (shortest side² × longest side)/2. For pre-and intra-operative tumor localization in the real-time resection, we conducted an in vivo tumor localization assay using the IRDye®-800CW 2-DG (2-deoxy-D-glucose) optical probe (LI-COR Biosciences, Lincoln, NE). Tumor localization was detected using optical imaging, particularly in the near-infrared fluorescence range. The tumorigenicity of MDA-MB-231-EV and MDA-MB-231-IL-32θ cells was assayed by intravenous injection of 1 × 10⁶ cells resuspended in PBS into nude mice (n = 5 per group).

Immunohistochemistry
Formalin-fixed, paraffin embedded tumor tissue sections from mice were immersed in citrate buffer and boiled for 4 min in a microwave to retrieve antigens. Endogenous peroxidase activity was blocked with 3% (v/v) H₂O₂ for 10 min. Non-specific binding sites were blocked with 1% BSA for 30 min. Sections were incubated with the appropriate primary antibodies at 4°C overnight and then the appropriate secondary antibodies for 1 h at RT. Diaminobenzidine tetrahydrochloride (Vector Laboratories, Burlingame, CA) was used as a substrate, and the sections were then counterstained with hematoxylin (MilliporeSigma).

Statistical analysis
Chi-square or Fisher’s exact test was used to evaluate the relationship between IL-32θ expression and clinicopathological status. The mRNA expression in tumor tissues and protein secretion in breast cancer patients’ sera were analyzed by Mann-Whitney U test. Student’s t-test were used to compare the two groups in in vitro and in vivo experiments. Statistical analyses were performed using GraphPad Prism software version 5.0. All p-values were two-sided, and p < 0.05 was interpreted as being statistically significant.
Results

Association between tumor IL-32 θ mRNA levels and breast tumor characteristics

To investigate whether IL-32 θ was expressed in the tissues of breast cancer patients, we performed RT-PCR analyses using our specific primers as described [17]. Of the total of 90 breast tumors examined, 35 tumors expressed IL-32 θ. The clinicopathological features and IL-32 θ expression profiles for all patients are summarized in Table 1. IL-32 θ expression was associated with tumor status, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) status, and molecular classification characteristics. Interestingly, IL-32 θ appeared frequently in ER negative, PR negative, HER-2 negative patients, and in those with triple negative-related breast cancer types (basal-like). Due to the lack of number of breast cancer patients with high metastasis status, the relationship between IL-32 θ and this status could not be assessed accurately. In general, IL-32 θ seemed to express in early tumor stage and be related to triple negative breast cancer types.

Opposing expression patterns of IL-32 θ and CCL18 in breast tumor tissues

Among the factors secreted by macrophages, CCL18 was reported to have strong effects on breast cancer progression whereas macrophage-secreted IL-1β, TNF-α, and CCL5 were previously suppressed by IL-32 θ [12, 18, 22, 23]; thus, mRNA expression levels of these factors were measured. To identify the relationship between IL-32 θ and breast cancer under the effect of TAMs, we

| Characteristic                       | Total | IL-32 θ expression | P-value |
|--------------------------------------|-------|--------------------|---------|
|                                      |       | Positive n (%)     | Negative n (%) |
|                                      | n = 90| n = 35             | n = 55             |
| Age                                  |       |                    |                   |
| > 60                                 | 9     | 4 (44.4)           | 5 (55.6)          | 0.7553³ |
| ≤ 60                                 | 81    | 31 (38.3)          | 50 (61.7)         |         |
| Tumor status                         |       |                    |                   |
| T0–1                                 | 29    | 16 (55.1)          | 13 (44.8)         | 0.0361¹ |
| T2–3                                 | 61    | 19 (31.1)          | 42 (68.9)         |         |
| Nodal status                         |       |                    |                   |
| N0–1                                 | 74    | 28 (37.8)          | 46 (62.2)         | 0.8036⁴ |
| N2–3                                 | 16    | 7 (43.8)           | 9 (56.3)          |         |
| Metastasis status                    |       |                    |                   |
| Yes                                  | 3     | 0 (0)              | 3 (100)           | 0.1674⁴ |
| No                                   | 87    | 35 (40.2)          | 52 (59.8)         |         |
| Estrogen receptor (ER)               |       |                    |                   |
| Positive                             | 64    | 18 (28.1)          | 46 (71.9)         | 0.001³  |
| Negative                             | 26    | 17 (65.4)          | 9 (34.6)          |         |
| Progesterone receptor (PR)           |       |                    |                   |
| Positive                             | 53    | 14 (26.4)          | 39 (73.6)         | 0.0037³ |
| Negative                             | 37    | 21 (56.8)          | 16 (43.2)         |         |
| Human epidermal growth factor receptor 2 (HER-2) |       |                    |                   |
| Positive                             | 56    | 17 (30.4)          | 39 (69.6)         | 0.0331⁴ |
| Negative                             | 34    | 18 (52.9)          | 16 (47.1)         |         |
| Molecular classification             |       |                    |                   |
| Luminal A (ER+ PR+/- HER-2- Ki67 low)| 20    | 9 (45)             | 11 (55)           | 0.04⁴  |
| Luminal B (ER+ PR+/- HER-2+ Ki67 high)| 44  | 11 (25)            | 33 (75)           |         |
| Basal-like (ER- PR- HER-2- EGFR+/Ki67 high) | 14  | 9 (64.3)           | 5 (35.7)          |         |
| HER2-enriched (ER-PR-HER-2+ Ki67 high) | 12  | 6 (50)             | 6 (50)            |         |

Data are presented as number of patients. EGFR, epidermal growth factor receptor. ¹Chi square test. ²Fisher exact test.
divided the breast tumor tissues in two groups according to CD206 expression (an M2 macrophage marker), with a CD206* status (n = 33) and CD206* tissues (n = 57) and measured CCL18, IL-1β, TNF-α, and CCL5 mRNA by RT-qPCR (Fig. 1a). The results showed that CCL18 mRNA expression was significantly higher in in CD206* group compared to CD206* group in opposition to IL-32θ expression (p < 0.05), whereas IL-1β, TNF-α, and CCL5 showed no difference between two groups (Fig. 1a). To clarify this relationship, the IL-32θ* patient group (n = 35) and IL-32θ* patient group (n = 55) were further assessed (Fig. 1b). Additionally, of the 55 serum samples collected

Fig. 1 Opposing expression patterns between IL-32θ and CCL18 in selected tumor tissues. The mRNA expression levels of IL-32θ in tumor tissues were determined by RT-PCR, and then quantitated using ImageJ software. mRNA expression levels of CCL-18, IL-1β, TNF-α, and CCL5 were quantitated by real-time PCR. **a** mRNA expression of IL-32θ in CD206* positive (n = 33) and negative (n = 57) tumor tissue groups. **b** mRNA expression in IL-32* positive (n = 35) and negative (n = 55) tumor tissue groups. **c** Protein secretion level of CCL18, IL-1β, TNF-α, and CCL5 in IL-32* positive (n = 17) and negative (n = 38) tumor tissue groups. Plot are box and whisker plots. A line drawn across the box represents the median. Statistics were analyzed using Mann-Whitney U test: *, p < 0.05
from breast cancer patients, protein secretion was measured in two groups IL-32β+ patients ($n = 17$) and IL-32γ+ patients ($n = 38$) (Fig. 1c). Results indicated that in the presence of IL-32β, CCL18 expression levels were lower than those without IL-32β while IL-1β, TNF-α, and CCL5 levels showed no difference between two groups. Unfortunately, secreted IL-1β and TNF-α were detected at very low level in the sera (Fig. 1c). These findings suggest that higher IL-32β expression in tumor tissue is accompanied by lower accumulation of CCL18 expression and vice versa while IL-1β or TNF-α or CCL5 expression are not affected by IL-32β.

**IL-32β reduces macrophage-regulated EMT, invasion, and migration in breast cancer cells in vitro**

MDA-MB-231, a triple negative breast cancer cell line, has mesenchymal-like phenotype and can undergo EMT to be more aggressive during tumor progression [24]; thus, we generated an MDA-MB-231 cell line stably expressing IL-32β to study the function of IL-32β in EMT. Due to the endogenous IL-32β expression in MDA-MB-231 cells [25], we used a specific primer set to recognize IL-32β and IL-32γ as described previously [17]. The IL-32β PCR product appeared at 299 bp, whereas the other isoforms appeared at 360 bp because the IL-32β sequence does not include exon 6, which is contained in IL-32γ (Fig. 2a). PMA-treated THP-1 macrophages were reported to show equivalent properties to M2 macrophages [26], and this similarity was confirmed in the present study (Additional file 1: Figure S1a–e). Based on this phenomenon, CM from PMA-treated THP-1 macrophages was used to stimulate MDA-MB-231 progression (Fig. 2b). The cellular morphology of MDA-MB-231 stably expressing IL-32β was observed without any stimulation, showing a more epithelial-like phenotype (Fig. 2c, upper panel). Consistent with previous research [12], MDA-MB-231 cells under CM treatment showed a more elongated shape and a mesenchymal-like phenotype compared to those in the non-treatment condition; however, IL-32β still moderated the morphological change to a more epithelial-like state (Fig. 2c, lower panel). Hence, it is assumed that IL-32β could potentially disrupt breast cancer EMT, invasion, and migration. For this reason, we evaluated whether IL-32β could regulate the epithelial marker, E-cadherin, and other tumor-promoting factors, COX-2 and MMP-9, stimulated by macrophages. As a result, the expression of E-cadherin under the stimulation of CM was downregulated in MDA-MB-231 EV cells as expected when MDA-MB-231 EV cells underwent EMT to become more aggressive, whereas it was significantly upregulated in MDA-MB-231-IL-32β cells (Fig. 2d-e). Significant downregulation of COX-2 and MMP-9 expression at the mRNA (Fig. 2d) and protein levels (Fig. 2e) were observed in MDA-MB-231-IL-32β cells as compared to MDA-MB-231 EV cells with or without CM stimulation. A decreasing pattern was also observed regarding MMP-9 enzyme activity visualized by zymography (Fig. 2f). Moreover, macrophage-derived CCL18 was reported to create a feedback loop between macrophage and breast cancer cells by stimulating breast cancer-derived GM-CSF [12]. In this study, the GM-CSF mRNA and secretion levels were found to be significantly upregulated in the presence of CM, which was markedly inhibited by IL-32β (Fig. 2d, g). To further determine the effects of IL-32β on cancer progression features, a transwell migration assay and a Matrigel invasion assay were performed (Fig. 2h-i). In the presence of CM, the stimulated MDA-MB-231-EV cells displayed increased rates of migration and invasion, and these rates were significantly reduced in MDA-MB-231-IL-32β cells (Fig. 2j). These data supported the role of IL-32β in suppressing macrophage-induced breast cancer progression.

**IL-32β directly interacts with PKCδ to subsequently inhibit NF-κB and STAT3 pathways in vitro**

To investigate the precise mechanism by which IL-32β might regulate breast cancer progression, the relationship between IL-32β and PKCδ in breast cancer cells was explored based on previous studies demonstrating their interaction [16, 19]. An immunoprecipitation assay showed that IL-32β could interact with only PKCδ upon PMA activation or CM stimulation in MDA-MB-231 IL-32β cells (Fig. 3a). Therefore, it was hypothesized that IL-32β interacted with PKCδ upon stimulation with THP-1 macrophage CM to subsequently modulate downstream pathways in breast cancer cells. Based on the transcription factors inhibited by IL-32β previously [17–19], NF-κB and STAT3 were assumed to be involved in the IL-32β-mediated PKCδ signaling. The western blot results revealed that in both CM treatment and non-treatment condition, IL-32β elevated IkBα expression, and inhibited phosphorylation of IkBα and STAT3 at tyrosine 705 (Fig. 3b). Next, the nuclear translocation levels of STAT3, p65 plus p50 (two subunits of NF-κB), which were increased remarkably in the treatment with CM, were downregulated by IL-32β (Fig. 3c). Further, immunofluorescence analysis was performed to determine the location of IL-32β, p65, and STAT3 in the nucleus and cytoplasm of MDA-MB-231 cells. The results were consistent with the western blot data, revealing that the fluorescence accumulation of p65 and STAT3 in the nucleus after stimulation with the CM was strongly reduced in IL-32β-expressing cells (Fig. 3d-e). To confirm that IL-32β regulated NF-κB and STAT3 through PKCδ, a pharmacological inhibition of PKCδ signaling by rottlerin [27] was applied before macrophage CM treatment. It was indicated that the PKCδ...
inhibitor could suppress IkBα degradation and STAT3 phosphorylation, and additional effects of rottlerin and IL-32 on these signals were also observed (Fig. 3b). These data demonstrated that PKCδ mediated NF-κB and STAT3 signaling, and IL-32 inhibited these pathways.

Blocking CCL18 signaling downregulates pro-malignancy factors and the PKCδ downstream pathway

The secretion levels of CCL18 were significantly detected in the supernatant of THP-1-derived macrophage activated by PMA compared to the untreated control (Additional file 1: Figure S1f). Therefore, it was assumed that macrophage-secreted CCL18 might play regulating roles in EMT, invasion, and migration through PKCδ signaling which was suppressed by IL-32θ. To support this idea, CCL18 signaling was blocked using a neutralizing antibody in co-treatment with CM in both MDA-MB-231 EV cells and MDA-MB-231-IL-32θ cells. The disappearance of CCL18 signaling in MDA-MB-231 EV cells significantly downregulated the expression of COX-2, MMP-9, GM-CSF, and upregulated E-cadherin at both mRNA and protein levels (Fig. 4a–d). Moreover, the degradation of IkBα, which represented the PKCδ downstream signaling, NF-κB, was strongly reduced while the phosphor-ylated STAT3 at tyrosine 705 was slightly downregulated in the absence of CCL18 in MDA-MB-231 EV cells (Fig. 4b). Furthermore, the absence of CCL18 in CM impaired the
effects of CM on the migration and invasion rates of MDA-MB-231 EV cells (Fig. 4e-f). These data suggest that CCL18 acts as an upstream activator of PKC\(\delta\) signaling (including two downstream pathways, NF-κB and STAT3) to induce breast cancer progression. The cytokine CCL18 seemed to influence NF-κB, and partly through STAT3 to stimulate E-cadherin, COX-2, MMP-9, and GM-CSF expression. Notably, IL-32\(\theta\) might collaborate with neutralizing CCL18 antibody to display additive effects in the decrease of the expression of metastasis-related factors in the MDA-MB-231 IL-32\(\theta\) cells as compared to that in the MDA-MB-231 EV cells (Fig. 4a-d). The results from migration and invasion assays, which were performed after blocking CCL18 signaling, indicated that the migration and invasion rates of the MDA-MB-231-IL-32\(\theta\) cells were reduced to the minimum when compared to the IgG treated control group (Fig. 4 e-f). Therefore, it can be confirmed that CCL18 signaling is the main target of IL-32\(\theta\) to inhibit the macrophage-induced metastasis of breast cancer cells.

**IL-32\(\theta\) inhibits tumor formation of breast cancer cells in vivo**

To examine the cancerous properties of MDA-MB-231-EV or MDA-MB-231-IL-32\(\theta\) cells, cells were injected to the flanks of mice in xenograft model (Fig. 5a). The immunohistochemistry results showed that the intensity of E-cadherin-positive cells was significantly increased, whereas the intensity for p65 and STAT3-positive cells were relatively decreased in the tumor tissue of the MDA-MB-231-IL-32\(\theta\) group compared to that of the

---

**Fig. 3** IL-32\(\theta\) interacts with PKC\(\delta\), and subsequently inhibits the NF-κB and STAT3 pathways in MDA-MB-231 cells. **a** IL-32\(\theta\) interacts with PKC\(\delta\) upon stimulation with PMA or CM. Immunoprecipitation was performed using anti-Myc antibody. **b-c** MDA-MB-231-EV and MDA-MB-231-IL-32\(\theta\) cells in the absence or presence of CM of THP-1 macrophages were harvested and separated into cytosol and nuclear fractions. NF-κB nuclear translocation and phosphorylation of IκB\(\alpha\) and STAT3 was detected by western blot. **d-e** Immunofluorescence assay to detect p65 (d) or STAT3 (e) (red) and Myc-IL-32\(\theta\) (green) localization (scale bar, 5 μm). Nuclei were stained with DAPI (blue). Western blot or immunofluorescence images are the representative results of three independent experiments.
MDA-MB-231-EV group (Fig. 5b). Moreover, tumor volume was reduced significantly in the mouse group injected with MDA-MB-231-IL-32θ cells (Fig. 5c). Furthermore, the mRNA levels of various tumor-promoting factors including COX-2, MMP-9, E-cadherin, and GM-CSF were down-regulated in the MDA-MB-231-IL-32θ group (Fig. 5d). These findings supported the idea that the antitumor activity of IL-32θ was associated with the inactivation of NF-κB and STAT3 in tumor tissues. In another model, the MDA-MB-231-EV or MDA-MB-231-IL-32θ cells were treated with macrophage CM for 24 h before intravenous injection to nude mice (Fig. 5e). As shown in Fig. 5f-g, MDA-MB-231-EV cell tumors were large and emitted strong fluorescence signal, whereas a weaker pattern was observed in the mice treated with MDA-MB-231-IL-32θ cells, suggesting potential effects of IL-32θ on the tumor progression of stimulated breast cancer cells.

Discussion

Macrophages, a major component of the tumor microenvironment, can initiate and support the tumor progression and metastasis by secreting a range of growth factors, cytokines, and chemokines [28]. IL-32 was found to not only target cancer cells but might also target the tumor microenvironment [29]. Recent reports showed the correlation and different functions of IL-32 and its isoforms to various cancer diseases. As an example, IL-32γ can inhibit colon cancer cell growth by targeting NF-κB and STAT3 pathways [30] while another isoform, IL-32β, stimulates the migration of breast cancer cells through VEGF-STAT3 [25], and is involved in the
increase of glycolysis under hypoxic conditions which supports cancer cell growth [31]. Given these data, it appears that the effects of IL-32 on tumor development depend on both its isoforms and cancer types; however, the exact mechanisms remain unclear. Our previous data on IL-32, a recently discovered isoform, demonstrated its inhibition ability in macrophage differentiation [32], macrophage-secreted factors [16, 18, 19], and in colon cancer progression by regulating self-renewal and EMT [17]. In this study, three isoforms, IL-32α, IL-32β, and IL-32γ, were detected at different mRNA levels in 90 breast tumors. IL-32β exhibited the strongest expression which was compatible with its protumor effects reported in breast cancer [25] while IL-32γ was rarely expressed compared to the IL-32α isoform (Additional file 1: Fig. S2a-c). Given this, the current study attempted to discover the role of IL-32α in breast cancer progression and its tumor microenvironment. Our clinical data showed that IL-32α expression was associated with the negativity of ER, PR, and HER-2, and with triple negative related breast cancer types. Based on this point, we chose MDA-MB-231 cells, a highly aggressive, basal-like breast cancer cells with triple negative background [33], together with PMA-treated THP-1 macrophage cells to mimic the interaction between macrophages and cancer cells within the tumor microenvironment and evaluate the role of IL-32α on this interaction in vitro. This basal-like cell line is associated with both a poor prognosis and clinical outcome, due to its aggressiveness and high rate of metastasis [34]. We determined that the EMT phenotypic changes of MDA-MB-231 cells caused by stimulation of CM from THP-1 macrophages could be inhibited by IL-32α. Moreover, invasion and migration rates were remarkably reduced in IL-32α-expressing cells after 24 h treatment with CM, suggesting that IL-32α could be a potential factor inhibiting macrophage-induced breast cancer progression. The

**Fig. 5** IL-32α inhibits tumor formation in a breast cancer xenograft model. **a** Schematic of mouse model 1: MDA-MB-231-EV and/or MDA-MB-231-IL-32α cells were injected into the flanks of mice (n = 10/group). Tumors from two mouse groups were extracted after 35 days and analyzed. **b** Images are presented from hematoxylin-eosin (HE) staining and immunohistochemistry staining of section from tumors. Immunohistochemistry images are the representative of ten sections. **c** Tumor size was measured after 35 days. **d** mRNA expression levels of pro-malignancy factors were quantitated by real-time PCR. **e** Schematic of mouse model 2: MDA-MB-231-EV and/or MDA-MB-231-IL-32α cells were treated with THP-1 CM for 24 h then probe administrated for 24 h before intravenous injection into mice (n = 5/group). **f** After 35 days, tumor localization was analyzed by IRDye®-2DG infrared optical probe-guided analysis. Representative imaging data of breast cancer cell-induced solid tumors in mice. **g** Fluorescence intensities were obtained by ImageJ software. Scale bar, 100 μm. Data are presented as the mean ± SEM and are analyzed using the Student’s t-test: *, p < 0.05.
interaction between macrophages and breast cancer cells has been reported to increase levels of various tumor promoting factors such as COX-2, and MMP-9 which, in turn, supports the breast malignancy and an increase of TAM density in the tumor microenvironment [23, 26, 28, 35]. In agreement with these reports, the present study indicated that IL-32θ downregulated COX-2, MMP-9, and E-cadherin expression in breast cancer cells stimulated by macrophages demonstrating a modulatory role of IL-32θ in breast cancer development.

In addition, the precise mechanism by which IL-32θ reduces the effects of macrophage on breast cancer progression was addressed based on previous studies detailing that IL-32θ interacted directly with PKCδ to subsequently decrease STAT3 or NF-κB signaling in PMA-activated THP-1 cells [16, 19]. In line with this theory, the present study showed a direct interaction between IL-32θ and PKCδ in breast cancer cells. Especially under CM treatment condition, IL-32θ inhibited phosphorylation of IκBα plus STAT3, and nuclear translocation of NF-κB and STAT3 in MDA-MB-231 cells (Fig. 3b). Moreover, interfering PKCδ signaling with rottlerin, a PKCδ inhibitor, resulted in additive effects with IL-32θ in the decrease of STAT3 phosphorylation and IκBα degradation. Due to the fact that PKCδ mRNA expression was found to be significantly higher in ER-positive compared with ER-negative tumors [36], we applied this model on another breast cancer cell line with an estrogen-dependent background, MCF-7. However, IL-32θ could not reduce any signal activated by macrophage CM in MCF-7 cells (Additional file 1: Figure S3a-b). Since MCF-7 represents epithelial-like cells and MDA-MB-231 represents mesenchymal-like cells, it is suggested that IL-32θ seemed to effectively modulate the breast cancer with EMT-associated macrophages, which is essential for metastasis. The lack of PKCδ activation in MDA-MB-231 in the non-stimulated condition disappeared when MDA-MB-231 was co-cultured with macrophage CM. Further studies are necessary to define the association between IL-32θ and mesenchymal-like cells but not epithelial-like cells. In any case, these findings demonstrated that IL-32θ targeted the interaction between macrophage and mesenchymal-like breast cancer, and there requires a specific macrophage-secreted factor to trigger PKCδ signaling in breast cancer which was inhibited by IL-32θ.

During the investigation of the IL-32θ-regulated signaling upstream factors, CCL18 was considered as a potential activator due to its presence in the THP-1 macrophage CM, and the inverse expression between IL-32θ and CCL18 in breast tumor tissues infiltrated with CD206+ macrophages. GM-CSF secreted from breast cancer cells activates macrophages to become CCL18-expressing TAM-like cells, which reciprocally supports GM-CSF secretion and furthers EMT of breast cancer cells [12]. Moreover, only GM-CSF significantly induced the production of TAM-related cytokines, and GM-CSF was found in CM from MDA-MB-231 cells but not MCF-7 cells [12]. Consistent with this study, our study found a decrease in the amount of GM-CSF secretion in IL-32θ-expressing MDA-MB-231 cells which might be stimulated by CCL18 from macrophages. Further, IL-32θ did not suppress endogenous GM-CSF in MDA-MB-231 cells due to a lack of PKCδ activation and interaction. The transcription factors STAT3 and NF-κB were also reported as the downstream factors regulated by PKCδ in cancer cells [37, 38]. In line with the idea that CCL18 is a stimulator of PKCδ signaling, our data demonstrated that blocking CCL18 signaling suppressed the expression of the PKCδ downstream factors STAT3 or NF-κB as well as various cancer-related factors. These results supported the idea that macrophage-secreted CCL18 might act as a stimulator of PKCδ signaling regulated by IL-32θ.

The present study also provides the first in vivo evidence of the suppressive function of IL-32θ in breast cancer. A xenograft mouse model of MDA-MB-231-IL-32θ cells showed an increase of E-cadherin-positive cells, suggesting that IL-32θ reversed the effects on EMT; whereas STAT3 and NF-κB-positive cells were much more abundant in the absence of IL-32θ. Another imaging model in which breast cancer cells were activated by macrophage CM to become more aggressive also supported that IL-32θ could reduce the tumor localization clearly compared to the MDA-MB-231-EV group. These in vivo results are in accordance with the in vitro and clinical data demonstrating that IL-32θ acts via PKCδ signaling to regulate the effects of macrophage-soluble factors on breast cancer cells.

The small population of patients’ data collected recently does not allow us to perform a survival analysis to assess the relationship between IL-32θ and the survival rate of breast cancer patients. Moreover, during studying about the effects of IL-32θ on breast cancer cell proliferation, we have found that Bcl-2, an anti-apoptotic factor which has been proposed as a prognostic marker [39], was totally repressed by IL-32θ in vitro (data not shown). However, no significant change between two cell lines could be seen in the expression levels of the late apoptotic markers after 72 h from flow cytometry results (data not shown). Thus, it is necessary to study different types of cell death to understand by which mechanism IL-32θ may affect the cell death. Finally, although there are some aspects described above to be considered, these will be the subjects of ongoing studies.
Conclusions
In conclusion, IL-32θ inhibited EMT and metastasis in breast cancer cells by targeting CCL18 secreted from macrophages. A schematic diagram of this mechanism was shown in Fig. 6. The IL-32θ-mediated inhibition of macrophage-breast cancer cross-talk shows potential for a therapeutic strategy in blocking pro-metastatic activity of breast cancer.

Additional files

**Additional file 1:** Table S1. PCR primer sequences. Figure S1. PMA-induced macrophages show an M2-like phenotype. Figure S2. mRNA expression of IL-32β, IL-32α, IL-32y in breast tumors. Figure S3. Effect of IL-32β on pro-malignancy and signaling factors in macrophage CM-treated MCF-7-EV and MCF-7-IL-32β cells. (PDF 514 kb)

**Additional file 2:** Raw data of Western blot. (PPTX 576 kb)

**Abbreviations**
CCL: Chemokine (C-C motif) ligand; CD206: Cluster of differentiation 206; CM: Conditioned media; COX-2: Cyclooxygenase 2; EMT: Epithelial-mesenchymal transition; GM-CSF: Granulocyte-macrophage colony-stimulating factor; IL: Interleukin; MMP-9: Matrix metalloproteinase 9; PKC: Protein kinase C; STAT3: Signal transducer and activator of transcription 3; TAMs: Tumor-associated macrophages

**Acknowledgements**
The biospecimens and characteristic data used for this study were provided by the Biobank of Chonnam National University Hwasun Hospital (Hwasun, Korea) and Korea University Guro Hospital (Seoul, Korea), members of the Korea Biobank Network.

**Authors’ contributions**
TP and YB performed most of the experiments, analyzed the results and wrote the manuscript. TK conducted the optical imaging experiments. SK established the stable cell line. JO supported in vitro materials and contributed to edit the manuscript. JP and YC participated in xenograft experiments. DY and JTH supervised the study. All authors read and approved the final manuscript.
Author's information
Not applicable.

Funding
This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean Government (2018R1A2B2001225).

Availability of data and materials
All results of this study are presented in this article and additional files.

Ethics approval and consent to participate
The protocol using biospecimens and related data in this study was approved by the Institutional Review Board (7001355–201704-E-047) of Konkuk University, and all subjects provided informed consent. All animal procedures were conducted according to the guidelines and approved by the Institutional Animal Care and Use Committee (IAUC No. IU17008) of Konkuk University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Bioscience and Biotechnology, Konkuk University, 120 Neungdong-ro, Jayang-dong, Gwangjin-gu, Seoul 05029, Republic of Korea. 2Primate Resource Center, Division of Bioinfrastructure, Korea Research Institute of Bioscience and Biotechnology (KRIIBB), Jeongeup, Jeollabuk-do, Republic of Korea. 3Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Seoul, Republic of Korea. 4Department of Laboratory Animal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea. 5College of Pharmacy and Medical Research Center, Chungbuk National University, Osongaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju, Chungbuk 28160, Republic of Korea.

Received: 17 March 2019 Accepted: 20 May 2019
Published online: 24 May 2019

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70:5649–50.
3. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12:895–904.
4. Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442.
5. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–12.
6. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–52.
7. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9:665–74.
8. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.
9. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grange MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949–55.
10. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo versus. J Clin Invest. 2012;122:787–95.
11. Biwi SW, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–96.
12. Su S, Liu Q, Chen J, Chen J, Chen F, He C, Huang D, Wu W, Lin L, Huang W, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell. 2014;25:605–20.
13. Kim SH, Han SY, Aztam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNF alpha. Immunity. 2005;22:131–42.
14. Kang JW, Park YS, Lee DH, Kim MS, Bak Y, Ham SY, Park SH, Kim H, Ahn JH, Hong JT, Yoon DY. Interaction network mapping among IL-32 isoforms. Biochimie. 2014;101:248–51.
15. Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. Pharmacol Ther. 2017;174:127–37.
16. Kim MS, Kang JW, Lee DH, Bak Y, Park YS, Song YS, Ham SY, Oh DK, Hong J, Yoon DY. IL-32theta negatively regulates IL-1beta production through its interaction with PKCdelta and the inhibition of PU.1 phosphorylation. FEBS Lett. 2014;588:2822–9.
17. Bak Y, Kwon T, Bak IS, Hong J, Yu DY, Yoon DY. IL-32theta inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer. Oncotarget. 2016;7:3707–17.
18. Kim MS, Kang JW, Jeon JS, Kim JK, Kim JW, Hong J, Yoon DY. IL-32theta gene expression in acute myeloid leukemia suppresses TNF-alpha production. Oncotarget. 2015;6:40747–61.
19. Kim Y, Kang JW, Kim MS, Park Y, Kwon T, Kim S, Hong J, Yoon DY, IL-32theta downregulates CCL5 expression through its interaction with PKCdelta and STAT3. Cell Signal. 2014;26:3007–15.
20. Kim KH, Shim JH, Seo EH, Cho MC, Kang JW, Kim SH, Yu DY, Song EY, Lee HG, Sohn JH, et al. Interleukin-32 monoclonal antibodies for immunohistochimistry, Western blotting, and ELISA. J Immunol Methods. 2008;333:38–50.
21. Kim JH, Kim MS, Bak Y, Chung JM, Yoon DY. The cadin-2-en-1beta-cel-1beta-D-gluconopyranoside suppresses TPA-mediated matrix metalloproteinase-9 expression through the ERK signaling pathway in MCF-7 human breast adenocarcinoma cells. J Pharmacol Sci. 2012;118:198–205.
22. Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis through PTNP3. Cancer Cell. 2011;19:541–55.
23. Gan L, Qiu Z, Huang J, Li Y, Huang H, Xiang T, Wan J, Hui T, Lin Y, Li H, Ren G. Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. Int J Biol Sci. 2016;12:1533–43.
24. Lacrix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat. 2004;83:249–89.
25. Park JS, Choi SY, Lee JH, Lee M, Nam ES, Jeong AL, Lee S, Han S, Lee MS, Lim JS, et al. Interleukin-32beta stimulates migration of MDA-MB-231 and MCF-7 cells via the VEGF-STAT3 signaling pathway. Cell Oncol (Dordr). 2013;36:493–503.
26. Tju JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chu HC, Dai YS, Inoue H, et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 2009;129:1016–25.
27. Konety E, Kurovska M, Szczepanska K, Mlasinski W, Rottlerin, a PKC isozyme-selective inhibitor, affects signaling events and cytokine production in human monocytes. J Leukoc Biol. 2000;67:249–58.
28. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71.
29. Yun HM, Oh JH, Shim JH, Ban JO, Park KR, Kim JH, Lee DH, Kang JW, Park YH, Yu D, et al. Antitumor activity of IL-32beta through the activation of lymphocytes, and the inactivation of NF-kappaB and STAT3 signals. Cell Death Dis. 2013;4:e640.
30. Oh JH, Cho MC, Kim JH, Lee SY, Kim HI, Park ES, Ban JO, Kang JW, Lee DH, Shim JH, et al. IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals. Oncogene. 2011;30:3845–59.
31. Park JS, Lee S, Jeong AL, Han S, Ka HJ, Lim JS, Lee MS, Yoon DY, Lee JH, Yang Y. Hypoasa-induced IL-32beta increases glycolysis in breast cancer cells. Cancer Lett. 2015;356:680–8.
32. Kim MS, Kang JW, Park YS, Lee DH, Bak Y, Kwon T, Yoon DY, IL-32theta inhibits monocyic differentiation of leukemia cells by attenuating expression of transcription factor PU.1. Oncotarget. 2015;6:4394–405.
33. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215.
34. Lissy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264–71.
35. Hou Z, Falcone DJ, Subbaramaiah K, Dannonberg AJ. Macrophages induce COX-2 expression in breast cancer cells: role of IL-1beta autoamplification. Carcinogenesis. 2011;32:695–702.
36. McKiernan E, O’Brien K, Grebenchtchikov N, Geurts-Moespot A, Sieuwerts AM, Martens JW, Magdolen V, Evoy D, McDermott E, Crown J, et al. Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA. Br J Cancer. 2008;99:1644–50.

37. Jain N, Zhang T, Kee WH, Li W, Cao X. Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner. J Biol Chem. 1999;274:24392–400.

38. Lu ZG, Liu H, Yamaguchi T, Miki Y, Yoshida K. Protein kinase Cdelta activates RelA/p65 and nuclear factor-kappaB signaling in response to tumor necrosis factor-alpha. Cancer Res. 2009;69:5927–35.

39. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010;103:668–75.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions